Sugi Predict

Sugi Predict / Compounds / SCHEMBL1978233

SCHEMBL1978233

SCHEMBL1978233

CC(C)(C)OC(=O)N1CCC[C@H](CBr)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ GLS O94925 2/20 0.52
▸ HPGD P15428 1/20 0.49
▸ BACE1 P56817 2/20 0.47
▸ ACKR3 P25106 1/20 0.47
▸ CTSD P07339 1/20 0.47
▸ NR1H2 P55055 1/20 0.47
▸ KDM1A O60341 1/20 0.45
▸ FEN1 P39748 1/20 0.45
▸ SCN9A Q15858 1/20 0.45
▸ EPHX1 P07099 1/20 0.43
▸ FPR3 P25089 1/20 0.43
▸ FPR2 P25090 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PREP P48147 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974493 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL376819 1.00 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL30294023 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL13604586 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1114093 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL14920966 0.91 NR1H2 (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7691100 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL758457 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7685622 0.88 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL25625800 0.87 NR1H2 (0.51) MEN1ALDH1A1MAPTKMT2AGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658640-A1 PYRIDIN-2(1H)-ONES AND PYRIMIDIN-4(3H)-ONES AS NLRP3 INHIBITORS Janssen Pharmaceutica NV (BE) 2025-12-10 — — EP disclosed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
WO-2024259246-A1 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF Transneural Therapeutics, Inc. (US) 2024-12-19 — — WO disclosed
CN-119039290-A P2X3 modulators 葛兰素史密斯克莱知识产权(第3号)有限公司 2024-11-29 — — CN disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
CN-118955490-A O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 渤健马萨诸塞州股份有限公司 2024-11-15 — — CN disclosed
WO-2024160693-A1 PYRIDIN-2(1H)-ONES AND PYRIMIDIN-4(3H)-ONES AS NLRP3 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-08 — — WO disclosed
CN-112218863-B O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors 比奥根MA公司 2024-07-12 — — CN disclosed
EP-3765458-B1 O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS BIOGEN MA INC (US) 2023-01-11 — — EP disclosed
EP-4103564-A1 P2X3 MODULATORS Bellus Health Cough Inc. (CA) 2022-12-21 — — EP disclosed
CN-115413279-A P2X3 modulators 贝卢斯医疗咳嗽病公司 2022-11-29 — — CN disclosed
US-11459324-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors BIOGEN MA INC. (US) 2022-10-04 — — US disclosed
CN-112218863-A O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranosidase inhibitors 比奥根MA公司 2021-01-12 — — CN disclosed
EP-3634962-A1 AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
WO-2018226998-A1 AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2018-12-13 — — WO disclosed
US-20110144136-A1 NOVEL ADENINE DERIVATIVES GLAXOSMITHKLINE LLC (US) 2011-06-16 — — US disclosed
US-20080176901-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2008-07-24 — — US disclosed
US-20080176901-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144136-A1 NOVEL ADENINE DERIVATIVES STING1, IFNG, IFNAR1 MEN1 1404/4885ALDH1A1 1606/4885MAPT 4840/4885
US-20080176901-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS PRSS1, PRSS8, PRSS2 MEN1 2897/4885ALDH1A1 3876/4885MAPT 1916/4885
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MEN1 1569/4885ALDH1A1 4471/4885MAPT 2999/4885
US-11459324-B2 O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors MGAT3, ST6GAL1, ST3GAL3 MEN1 3362/4885ALDH1A1 417/4885MAPT 4812/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MEN1 1569/4885ALDH1A1 4471/4885MAPT 2999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.